Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

Authors:

Abstract
Background Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralises interleukin‐17A. Objective To assess the efficacy and safety of different maintenance‐dosing regimens of secukinumab 300 mg based on PASI response at Week 24 in patients with moderate to severe plaque psoriasis. Methods OPTIMISE was a randomised, open‐label, rater‐blinded Phase 3b study. Subjects (n=1,647) received secukinumab 300 mg at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks (q4w) to Week 24. At Week 24, PASI 90 responders (n=1306) were randomised to secukinumab 300 mg q4w (n=644) or every 6 weeks (q6w, n=662) regimen to Week 52; PASI ≥75 to P=0.1013). Heavier subjects (≥90 kg) demonstrated numerically higher PASI 90 response with q2w (57.1%) vs q4w regimen (39.6%, P=0.1053). Conclusion Standard q4w dosing of secukinumab 300 mg is the optimal dosing regimen to achieve and maintain clear or almost clear skin. Subjects with body weight ≥90 kg not achieving PASI 90 at Week 24 may benefit from the q2w dosing regimen.

This publication has 28 references indexed in Scilit: